Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

NICE approves a new option for rheumatoid arthritis

bs_subtitle

NICE has issued a positive Final Appraisal Determination (FAD) recommending RoActemra monotherapy for patients with severe rheumatoid arthritis (RA) for use on the NHS.  The decision is based on a dossier of data that included results which show RoActemra helps almost four times as many patients achieve remission than those treated with a leading anti-TNF monotherapy. The guidance brings England and Wales in line with Scotland, where RoActemra has been available as monotherapy or in combination with methotrexate to Scottish patients for a year.  RoActemra is a first of its kind biologic and the only interleukin-6 (IL-6) receptor antagonist licensed for the treatment of patients

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy